In September 2024 Africa CDC and IAVI announced the signing of a Memorandum of Understanding (MoU) to enhance the continent’s capacity to fight disease, pandemic readiness, and supply resilience. This will involve expanding capabilities for locally driven research, development, manufacturing, and supply of priority vaccines and antibodies as well as strengthening Africa CDC-led initiatives. The partnership will combine IAVI’s “expertise in vaccine and antibody development and access” and the “extensive network and Africa CDC”.  

Initiatives under the MoU 

The MoU is intended to tackle pressing public health challenges and promote long-term health security. Some of the key initiatives under the MoU include: 

  • Supporting the development of vaccines and antibodies for regional health priorities (like Lassa fever and HIV) 
  • Fostering a sustainable supply and demand ecosystem for priority products in the region (including monoclonal antibodies) 
  • Strengthening African research and development capacity  
  • Exploring regional stockpile strategies for licensed and investigational products to ensure rapid responses during health crises 

The MoU exemplifies the “action-oriented partnerships” that Africa CDC’s New Public Health Order demands as the organisation drives its vision for “redefining global health architecture” and ensuring that Africa and the world are better prepared for future health threats. IAVI recognises the support of funders and partners, including Wellcome, CEPI, the European and Developing Countries Clinical Trials Partnership (EDCTP), the United States Agency for International Development (USAID) and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) through the Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic (ADVANCE) programme.  

Dr Mark Feinberg, IAVI President and CEO, described the cooperation as a “key step” in IAVI’s mission to “improve global access to biomedical innovations and safeguard public health”. 

“It goes beyond R&D; it’s about creating a vibrant health innovation ecosystem that meets current and future needs across Africa.” 

We look forward to welcoming senior representatives of IAVI back to the Congress in Barcelona next month to learn more about the various efforts and initiatives they are enabling in pursuit of global health goals. Get your tickets to join us there and don’t forget to subscribe to our weekly newsletters here.  

Discover more from VaccineNation

Subscribe now to keep reading and get access to the full archive.

Continue reading